@SDNYnews issued an important decision involving the AKS last night. Read @EleanorLaise's excellent summary of the ruling and see why I think the court may have left the door open for pharma to challenge unfavorable OIG advisory opinions in the future.
How can #hospitals and health systems identify opportunities to apply the new rules for value-based arrangements? Our #Healthcare attorneys will share best practices in a webinar on Oct. 6. Register now: https://t.co/bE9OofeIz0
#HealthcareLaw
HHS’s Efforts to Reduce Prescription Drug Prices and Transition to Value-Based Care – Part 1: CMS & OIG Issue Final Rules - Attorneys Anjali Downs, @J_E_Michael, Victoria Sheridan, Lesley Yeung.
#healthcare#pharma#healthinsurance#valuebasedcare
https://t.co/FOvetWXEkh
OIG and CMS issued their long-awaited rules in connection with the Regulatory Sprint today. MedTech Dive included a quote from my early analysis. Stay tuned for an in-depth analysis from the health care fraud and abuse lawyers at Epstein Becker & Green.